share_log

Vanda Pharmaceuticals (NASDAQ:VNDA) Trading Up 4.8%

Vanda Pharmaceuticals (NASDAQ:VNDA) Trading Up 4.8%

萬達製藥(納斯達克：VNDA)股價上漲4.8%
Financial News Live ·  2022/08/30 12:41

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Get Rating)'s stock price was up 4.8% during trading on Tuesday . The stock traded as high as $10.98 and last traded at $10.95. Approximately 4,637 shares traded hands during trading, a decline of 99% from the average daily volume of 382,612 shares. The stock had previously closed at $10.45.

在週二的交易中，萬達製藥股份有限公司(納斯達克代碼：VNDA-GET Rating)的股價上漲了4.8%。該股盤中一度漲至10.98美元，最新報10.95美元。該股全天約有4,637股易手，較382,612股的日均成交量下降了99%。此前該股收盤價為10.45美元。

Analyst Upgrades and Downgrades

分析師升級和下調評級

Separately, StockNews.com upgraded shares of Vanda Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Friday, June 3rd.

另外，在6月3日週五的一份研究報告中，StockNews.com將萬達製藥的股票評級從持有上調至買入。

Get
到達
Vanda Pharmaceuticals
萬達製藥
alerts:
警報：

Vanda Pharmaceuticals Trading Up 4.3 %

萬達製藥股價上漲4.3%

The stock has a market cap of $616.50 million, a price-to-earnings ratio of 52.25 and a beta of 0.47. The stock's 50-day moving average price is $10.80 and its 200-day moving average price is $10.89.

該股市值為6.165億美元，市盈率為52.25倍，貝塔係數為0.47。該股的50日移動均線價格為10.80美元，200日移動均線價格為10.89美元。

Insider Transactions at Vanda Pharmaceuticals

萬達製藥的內幕交易

In other news, Director Stephen Ray Mitchell sold 2,700 shares of the business's stock in a transaction that occurred on Monday, June 13th. The shares were sold at an average price of $9.48, for a total value of $25,596.00. Following the transaction, the director now owns 6,515 shares in the company, valued at approximately $61,762.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Stephen Ray Mitchell sold 2,700 shares of the business's stock in a transaction that occurred on Monday, June 13th. The shares were sold at an average price of $9.48, for a total value of $25,596.00. Following the transaction, the director now owns 6,515 shares in the company, valued at approximately $61,762.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CMO Joakim Wijkstrom sold 3,605 shares of the business's stock in a transaction that occurred on Monday, August 22nd. The stock was sold at an average price of $10.27, for a total transaction of $37,023.35. Following the completion of the transaction, the chief marketing officer now owns 96,673 shares in the company, valued at approximately $992,831.71. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 8,544 shares of company stock worth $87,181. Company insiders own 7.00% of the company's stock.
在其他新聞方面，董事斯蒂芬·雷·米切爾在6月13日(星期一)的一筆交易中出售了2,700股該公司的股票。這些股票的平均價格為9.48美元，總價值為25,596.00美元。交易完成後，董事現在擁有該公司6,515股股份，價值約61,762.20美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，用户可以通過美國證券交易委員會網站查看該文件。在其他新聞方面，董事斯蒂芬·雷·米切爾在6月13日(星期一)的一筆交易中出售了2,700股該公司的股票。這些股票的平均價格為9.48美元，總價值為25,596.00美元。交易完成後，董事現在擁有該公司6,515股股份，價值約61,762.20美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，用户可以通過美國證券交易委員會網站查看該文件。此外，首席營銷官Joakim Wijkstrom在8月22日星期一的一次交易中出售了3605股該公司的股票。該股以10.27美元的平均價格出售，總成交金額為37,023.35美元。交易完成後，首席營銷官現在擁有該公司96,673股股票，價值約992,831.71美元。此次拍賣的披露信息可在此處找到。在過去的90天裏，內部人士出售了8,544股公司股票，價值87,181美元。公司內部人士持有該公司7.00%的股份。

Institutional Inflows and Outflows

機構資金流入和流出

A number of institutional investors have recently modified their holdings of the stock. Wedge Capital Management L L P NC lifted its position in shares of Vanda Pharmaceuticals by 8.8% during the 2nd quarter. Wedge Capital Management L L P NC now owns 11,206 shares of the biopharmaceutical company's stock valued at $122,000 after acquiring an additional 902 shares during the period. Ziegler Capital Management LLC increased its stake in Vanda Pharmaceuticals by 2.6% during the 2nd quarter. Ziegler Capital Management LLC now owns 39,454 shares of the biopharmaceutical company's stock valued at $430,000 after purchasing an additional 1,016 shares in the last quarter. Texas Permanent School Fund increased its stake in Vanda Pharmaceuticals by 2.8% during the 2nd quarter. Texas Permanent School Fund now owns 40,591 shares of the biopharmaceutical company's stock valued at $442,000 after purchasing an additional 1,094 shares in the last quarter. Comerica Bank increased its stake in Vanda Pharmaceuticals by 2.5% during the 1st quarter. Comerica Bank now owns 47,706 shares of the biopharmaceutical company's stock valued at $537,000 after purchasing an additional 1,180 shares in the last quarter. Finally, Yousif Capital Management LLC increased its stake in Vanda Pharmaceuticals by 2.4% during the 1st quarter. Yousif Capital Management LLC now owns 50,710 shares of the biopharmaceutical company's stock valued at $574,000 after purchasing an additional 1,180 shares in the last quarter. Institutional investors and hedge funds own 99.42% of the company's stock.

一些機構投資者最近調整了對該股的持有量。Wdge Capital Management L L P NC在第二季度將其在Vanda PharmPharmticals股票的頭寸提高了8.8%。韋奇資本管理公司現在擁有11,206股這家生物製藥公司的股票，價值122,000美元，在此期間又購買了902股。Ziegler Capital Management LLC在第二季度增持了2.6%的萬達製藥股份。Ziegler Capital Management LLC現在持有這家生物製藥公司39,454股股票，價值43萬美元，上個季度又購買了1,016股。德州永久學校基金在第二季度增持了2.8%的萬達製藥股份。德克薩斯永久學校基金在上個季度又購買了1,094股後，現在擁有40,591股這家生物製藥公司的股票，價值442,000美元。Comerica銀行在第一季度增持了2.5%的Vanda PharmPharmticals股份。Comerica銀行現在持有這家生物製藥公司47,706股股票，價值537,000美元，上個季度又購買了1,180股。最後，Yousif Capital Management LLC在第一季度增持了2.4%的Vanda PharmPharmticals股份。Yousif Capital Management LLC現在擁有50,710股這家生物製藥公司的股票，價值57.4萬美元，上個季度又購買了1,180股。機構投資者和對衝基金持有該公司99.42%的股票。

About Vanda Pharmaceuticals

關於萬達製藥

(Get Rating)

(獲取評級)

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.

萬達製藥公司是一家生物製藥公司，專注於療法的開發和商業化，以滿足高度未得到滿足的醫療需求。該公司的營銷產品包括用於治療非24小時睡眠-覺醒障礙的Hetlioz；以及用於治療精神分裂症的Fanapt口服藥片。

Recommended Stories

推薦故事

  • Get a free copy of the StockNews.com research report on Vanda Pharmaceuticals (VNDA)
  • Shock Absorbers: 3 Low Volatility Dividend Stocks for Bumpy Times
  • The Retail Sector: Winners And Losers From Q2 Earnings
  • Can Targa Continue Rallying To Meet Its Price Target?
  • Is Unity Software Ready To Rally After Rejecting AppLovin Offer?
  • MarketBeat Podcast: The Time For Cloud Stocks May Be Now
  • 免費獲取StockNews.com關於萬達製藥的研究報告(VNDA)
  • 減震器：顛簸時代的3只低波動率紅利股票
  • 零售業：第二季度收益的贏家和輸家
  • Targa能否繼續反彈以實現其價格目標？
  • 在拒絕了AppLovin的報價後，Unity Software準備好重整旗鼓了嗎？
  • MarketBeat播客：雲股票的時代可能就是現在

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

獲得《Vanda PharmPharmticals Daily》新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Vanda PharmPharmticals和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論